Fatima Cody Stanford1, Nasreen Alfaris2, Gricelda Gomez3, Elizabeth T Ricks4, Alpana P Shukla5, Kathleen E Corey6, Janey S Pratt7, Alfons Pomp8, Francesco Rubino9, Louis J Aronne10. 1. MGH Weight Center, Gastrointestinal Unit-Department of Medicine, Massachusetts General Hospital, Boston, MA; Endocrine Unit, Department of Pediatrics, Massachusetts General Hospital, Boston, MA; Harvard Medical School, Boston, MA. Electronic address: fstanford@mgh.harvard.edu. 2. MGH Weight Center, Gastrointestinal Unit-Department of Medicine, Massachusetts General Hospital, Boston, MA; Harvard Medical School, Boston, MA; Obesity, Metabolism and Nutrition Institute, Massachusetts General Hospital, Boston, MA. 3. Harvard Medical School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA. 4. Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Weill Cornell Medical College, New York, NY; Institute of Human Nutrition, Columbia University, New York, NY; Texas Tech University- Paul L. Foster School of Medicine, El Paso, TX. 5. Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Weill Cornell Medical College, New York, NY. 6. Harvard Medical School, Boston, MA; Gastrointestinal Unit-Department of Medicine, Massachusetts General Hospital, Boston, MA. 7. Harvard Medical School, Boston, MA; Department of Surgery, Massachusetts General Hospital, Boston, MA. 8. Department of GI Metabolic and Bariatric Surgery, Weill Cornell Medical College, New York, NY. 9. Department of Metabolic and Bariatric Surgery, Kings College London and Kings College Hospital, London, UK. 10. Institute of Human Nutrition, Columbia University, New York, NY.
Abstract
BACKGROUND: Patients who undergo bariatric surgery often have inadequate weight loss or weight regain. OBJECTIVES: We sought to discern the utility of weight loss pharmacotherapy as an adjunct to bariatric surgery in patients with inadequate weight loss or weight regain. SETTING: Two academic medical centers. METHODS: We completed a retrospective study to identify patients who had undergone bariatric surgery in the form of a Roux-en-Y gastric bypass (RYGB) or a sleeve gastrectomy from 2000-2014. From this cohort, we identified patients who were placed on weight loss pharmacotherapy postoperatively for inadequate weight loss or weight regain. We extracted key demographic data, medical history, and examined weight loss in response to surgery and after the initiation of weight loss pharmacotherapy. RESULTS: A total of 319 patients (RYGB = 258; sleeve gastrectomy = 61) met inclusion criteria for analysis. More than half (54%; n = 172) of all study patients lost≥5% (7.2 to 195.2 lbs) of their total weight with medications after surgery. There were several high responders with 30.3% of patients (n = 96) and 15% (n = 49) losing≥10% (16.7 to 195.2 lbs) and≥15% (25 to 195.2 lbs) of their total weight, respectively, Topiramate was the only medication that demonstrated a statistically significant response for weight loss with patients being twice as likely to lose at least 10% of their weight when placed on this medication (odds ratio = 1.9; P = .018). Regardless of the postoperative body mass index, patients who underwent RYGB were significantly more likely to lose≥5% of their total weight with the aid of weight loss medications. CONCLUSIONS: Weight loss pharmacotherapy serves as a useful adjunct to bariatric surgery in patients with inadequate weight loss or weight regain.
BACKGROUND:Patients who undergo bariatric surgery often have inadequate weight loss or weight regain. OBJECTIVES: We sought to discern the utility of weight loss pharmacotherapy as an adjunct to bariatric surgery in patients with inadequate weight loss or weight regain. SETTING: Two academic medical centers. METHODS: We completed a retrospective study to identify patients who had undergone bariatric surgery in the form of a Roux-en-Y gastric bypass (RYGB) or a sleeve gastrectomy from 2000-2014. From this cohort, we identified patients who were placed on weight loss pharmacotherapy postoperatively for inadequate weight loss or weight regain. We extracted key demographic data, medical history, and examined weight loss in response to surgery and after the initiation of weight loss pharmacotherapy. RESULTS: A total of 319 patients (RYGB = 258; sleeve gastrectomy = 61) met inclusion criteria for analysis. More than half (54%; n = 172) of all study patients lost≥5% (7.2 to 195.2 lbs) of their total weight with medications after surgery. There were several high responders with 30.3% of patients (n = 96) and 15% (n = 49) losing≥10% (16.7 to 195.2 lbs) and≥15% (25 to 195.2 lbs) of their total weight, respectively, Topiramate was the only medication that demonstrated a statistically significant response for weight loss with patients being twice as likely to lose at least 10% of their weight when placed on this medication (odds ratio = 1.9; P = .018). Regardless of the postoperative body mass index, patients who underwent RYGB were significantly more likely to lose≥5% of their total weight with the aid of weight loss medications. CONCLUSIONS:Weight loss pharmacotherapy serves as a useful adjunct to bariatric surgery in patients with inadequate weight loss or weight regain.
Authors: Barham K Abu Dayyeh; Pichamol Jirapinyo; Zachary Weitzner; Charlotte Barker; Michael S Flicker; David B Lautz; Christopher C Thompson Journal: Gastrointest Endosc Date: 2012-08 Impact factor: 9.427
Authors: R Padwal; S Klarenbach; N Wiebe; D Birch; S Karmali; B Manns; M Hazel; A M Sharma; M Tonelli Journal: Obes Rev Date: 2011-03-28 Impact factor: 9.213
Authors: Peter T Hallowell; Thomas A Stellato; David A Yao; Ann Robinson; Margaret M Schuster; Kristen N Graf Journal: Am J Surg Date: 2009-03 Impact factor: 2.565
Authors: Jacqueline Odom; Kerstyn C Zalesin; Tamika L Washington; Wendy W Miller; Basil Hakmeh; Danielle L Zaremba; Mohamed Altattan; Mamtha Balasubramaniam; Deborah S Gibbs; Kevin R Krause; David L Chengelis; Barry A Franklin; Peter A McCullough Journal: Obes Surg Date: 2009-06-25 Impact factor: 4.129
Authors: Rena R Wing; Wei Lang; Thomas A Wadden; Monika Safford; William C Knowler; Alain G Bertoni; James O Hill; Frederick L Brancati; Anne Peters; Lynne Wagenknecht Journal: Diabetes Care Date: 2011-05-18 Impact factor: 19.112
Authors: Nasreen Alfaris; Thomas A Wadden; David B Sarwer; Lisa Diwald; Sheri Volger; Patricia Hong; Amber Baxely; Alyssa M Minnick; Marion L Vetter; Robert I Berkowitz; Jesse Chittams Journal: Obesity (Silver Spring) Date: 2015-01-22 Impact factor: 5.002
Authors: Maria Paula Carlin Cambi; Giorgio Alfredo Pedroso Baretta; Daniéla De Oliveira Magro; Cesar Luiz Boguszewski; Igor Braga Ribeiro; Pichamol Jirapinyo; Diogo Turiani Hourneaux de Moura Journal: Obes Surg Date: 2021-01-03 Impact factor: 4.129
Authors: Nawfal W Istfan; Wendy A Anderson; Donald T Hess; Liqun Yu; Brian Carmine; Caroline M Apovian Journal: Obesity (Silver Spring) Date: 2020-06 Impact factor: 5.002
Authors: Janey S A Pratt; Allen Browne; Nancy T Browne; Matias Bruzoni; Megan Cohen; Ashish Desai; Thomas Inge; Bradley C Linden; Samer G Mattar; Marc Michalsky; David Podkameni; Kirk W Reichard; Fatima Cody Stanford; Meg H Zeller; Jeffrey Zitsman Journal: Surg Obes Relat Dis Date: 2018-03-23 Impact factor: 4.734